Vytorin Continues To Grow Globally As Schering Seeks Ways To ENHANCE U.S. Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Cholesterol franchise is up 6 percent overall as Zetia and Vytorin prescription sales drop 5 percent in the U.S. in the wake of negative trial results.